BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27650502)

  • 1. Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53.
    Ogasawara MA; Liu J; Pelicano H; Hammoudi N; Croce CM; Keating MJ; Huang P
    Mitochondrion; 2016 Nov; 31():33-39. PubMed ID: 27650502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.
    Liu J; Chen G; Pelicano H; Liao J; Huang J; Feng L; Keating MJ; Huang P
    Oncotarget; 2016 Nov; 7(44):71378-71389. PubMed ID: 27655686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
    Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
    Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
    Liu J; Chen G; Feng L; Zhang W; Pelicano H; Wang F; Ogasawara MA; Lu W; Amin HM; Croce CM; Keating MJ; Huang P
    Leukemia; 2014 Jan; 28(1):118-28. PubMed ID: 23608884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated
    Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
    FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective dysfunction of p53 for mitochondrial biogenesis induces cellular proliferation in bronchial smooth muscle from asthmatic patients.
    Trian T; Allard B; Ozier A; Maurat E; Dupin I; Thumerel M; Ousova O; Gillibert-Duplantier J; Le Morvan V; Begueret H; Girodet PO; Marthan R; Berger P
    J Allergy Clin Immunol; 2016 Jun; 137(6):1717-1726.e13. PubMed ID: 26688517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
    Carew JS; Nawrocki ST; Xu RH; Dunner K; McConkey DJ; Wierda WG; Keating MJ; Huang P
    Leukemia; 2004 Dec; 18(12):1934-40. PubMed ID: 15483672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
    Merkel O; Wacht N; Sifft E; Melchardt T; Hamacher F; Kocher T; Denk U; Hofbauer JP; Egle A; Scheideler M; Schlederer M; Steurer M; Kenner L; Greil R
    Leukemia; 2012 Dec; 26(12):2508-16. PubMed ID: 22743622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
    Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
    Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
    Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
    Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.